SDS
2.11.2020 13:32:04 CET | Business Wire | Press release
SDS today announced it has earned Oracle Exadata Optimized status through Oracle PartnerNetwork (OPN), demonstrating that SDS GEOS 7.9.0 has been tested and tuned on Oracle Exadata Database Machine to deliver speed, scalability, and reliability to customers. SDS is a Platinum level member of OPN.
Only a few companies manage to set new digital standards with the disruptive change happening in the financial industry and at the same time guarantee security in maximum performance dimensions. As part of a proof of concept (PoC) conducted at the Oracle Solutions Center, the throughput of SDS GEOS securities order processing was measured. The test of SDS GEOS 7.9.0 was conducted on an Oracle Exadata X8M configured as a database system with a two-node RAC, with a total of 32 CPU cores and 64GB memory assigned to the workload, which resulted in a more than convincing throughput of 795.9 orders/sec compared to the currently acceptable 100 to 400 orders per second. This clearly demonstrates that SDS GEOS runs very efficiently on Oracle Exadata Database Machine and that SDS is a future-proof and secure partner for the highest workloads.
Oracle Exadata Optimized is part of the Oracle Exastack Optimized program which enables partners, such as SDS, to leverage OPN enablement resources and dedicated lab environments to help develop, test, and tune their applications on Oracle Exadata engineered systems.
By achieving Oracle Exadata Optimized status, Oracle recognizes SDS for developing, testing, and tuning SDS GEOS on Oracle Exadata. This accomplishment is a testament to SDS’s ability to deliver the extreme performance and reliability customers require.
"Together with Oracle, SDS was able to test a new performance dimension in the processing of securities orders. This is a very important indicator that shows the limits of the performance of banking systems and associated transaction service providers can be surpassed, especially when needed in a volatile and strongly crisis-driven trading environment. A level of around 100 to 400 orders per second is usually sufficient for large securities traders in the most significant financial markets in Europe to guarantee their customers an immediate dispatch to the trading center even in times of extremely high order volumes. This requirement was outperformed by up to 700% in our laboratory test, providing clear evidence that SDS GEOS runs very efficiently on Oracle and that SDS is a future-proof and secure partner for the highest workloads in this technology stack," comments SDS Managing Director Ernst Kendlbacher on the results for Oracle Exastack Optimized.
“Oracle Exastack Optimized recognizes partners who have optimized their solutions on a complete, integrated and cloud-ready infrastructure in order to help them accelerate innovation, unlock new features and functionality, and deliver superior value to users,” said David Hicks, Vice President, Worldwide ISV Ecosystem Business Development, Oracle. “By achieving Oracle Exadata Optimized status, SDS has demonstrated that SDS GEOS is tested and tuned to work with Oracle Exadata to help deliver optimum performance, scalability, and reliability to their customers.”
To find out more, please visit http://www.sds.at or http://www.oracle.com/partners/goto/exastack or http://www.oracle.com/partners .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005489/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing23.3.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Contour* for the correction of temple hollowing, expanding its use beyond cheek augmentation and midface contour deficiencies to support overall facial balance and harmony1-3 The approval is based on clinical data showing Restylane Contour, part of Galderma’s versatile portfolio of hyaluronic acid injectables, delivers natural-looking results lasting for up to 18 months and high patient satisfaction1,2 This follows the recent U.S. FDA approval for Restylane Lyft™ for the enhancement of the chin profile and the debut of the ‘Wake Up to Restylane’ campaign in the U.S., highlighting Galderma’s commitment to continuing to evolve this versatile portfolio to meet emerging and diverse needs, including the desire for effortless, ‘wake‑up‑ready’ beauty4 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hol
Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 05:00:00 CET | Press release
Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a
Andersen Consulting styrker sit cybersikkerhedstilbud gennem samarbejde med Trillium Information Security Systems21.3.2026 02:16:00 CET | Pressemeddelelse
Andersen Consulting udbygger sine kompetencer inden for teknologi og risikostyring gennem en samarbejdsaftale med Trillium Information Security Systems (TISS), et cybersikkerhedsfirma. Med en tilstedeværelse i Canada og Pakistan leverer TISS omfattende cybersikkerhedsløsninger til organisationer inden for finans, telekommunikation og den offentlige sektor. Virksomhedens team tilbyder et bredt udvalg af ydelser, herunder sikkerhedsvurderinger, managed security operations, red team-tjenester, digital efterforskning og hændelsesrespons samt GRC-rådgivning. Med næsten to årtiers erfaring leverer TISS adaptive, efterretningsdrevne forsvarsmekanismer, der hjælper kunder med at forudse og reagere på cybertrusler, der er i konstant udvikling. "Hos TISS arbejder vi på at skabe et mere sikkert digitalt miljø ved at give organisationer mulighed for at operere sikkert og med selvtillid," udtalte Mahir Mohsin Sheikh, administrerende direktør for TISS. "Vores samarbejde med Andersen Consulting giver
Andersen Consulting udvider sin teknologiplatform i Frankrig20.3.2026 17:28:00 CET | Pressemeddelelse
Andersen Consulting udvider sit udbud inden for digital transformation med en samarbejdsaftale med Teolia Consulting, et fransk firma, der specialiserer sig i projekt- og produktstyring, cloud-platformsudvikling, datatransformation samt implementering og brug af Atlassian-pakken. Teolia Consulting blev grundlagt i 2014 og hjælper organisationer med at opnå digital performance, fra agile metoder til løsninger, der reducerer lanceringstiden. Virksomhedens ekspertise består i at levere integrerede strategier, der bringer teknologi og organisatorisk forandring i overensstemmelse. Virksomheden arbejder på tværs af brancher, herunder inden for bank- og finanssektoren, forsikring, mode og detailhandel, og hjælper kunder med at få større robusthed og accelerere deres digitale modenhed. "Hos Teolia Consulting mener vi, at ægte transformation opstår, når teknologi og mennesker udvikler sig sammen," sagde Lucienne Jacquet, der er administrerende partner i Teolia. "Ved at samarbejde med Andersen C
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom